drugset / Trial / NCT00490425

Prevention of Asthma and Allergy by Probiotic Lactobacillus GG

NCT00490425 ↗

Phase 4 Completed 131 enrolled Johann Wolfgang Goethe University Hospital
RandomizedParallel-groupDouble-blindPrevention

Summary

Given that asthma results from a complex interaction between genetic susceptibility and environmental factors and rates of childhood asthma are increasing, primary prevention has to focus on modifiable aspects such as nutrition. There a implications from epidemiology that food supplementation with probiotics given to atopic mothers in pregnancy and during lactation can prevent the development allergies in the offspring. Children with atopic dermatitis are at increased risk (up to 80%) of developing persistent respiratory tract disease. Our trial examined whether probiotics are able to prevent allergic sensitization and allergic asthma when given to 6-24 month old infants at an increased risk of allergies.

Timeline

Start
2002-10
Primary completion
—
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Lactobacillus rhamnosus strain GG ATCC 53103 Other / unclassified 1010 unknown Oral

Indications